Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis

PHASE4CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
SchizophreniaProdrome
Interventions
DRUG

Omega 3 fatty acids

The active treatment is a supplement of yellow gelatin 0.5 g fish oil capsules. The daily dose of 4 (2x2) capsules provides 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid, and 10 mg of Vitamin E. Placebo treatment comprises coconut oil capsules, carefully matched with the active treatment with respect to both appearance and flavor, also containing 10 mg Vitamin E, and 10 mg of fish oil to mimic taste. Coconut oil was chosen as placebo because it does not contain polyunsaturated fatty acids and has no impact on n-3 fatty acid metabolism. The intervention period is 12 weeks.

Trial Locations (1)

1090

Medical University of Vienna, Department of Child and Adolescent Psychiatry, Vienna

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

Medical University of Vienna

OTHER

NCT00396643 - Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis | Biotech Hunter | Biotech Hunter